{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:59:18Z","timestamp":1789502358821,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>BRAF V600E<\/jats:italic>\n                      mutation is a key oncogenic driver commonly found in papillary thyroid carcinoma (PTC) and anaplastic thyroid carcinoma (ATC). Dabrafenib plus trametinib combination therapy targeting this mutation has shown promising activity in clinical trials. This study aimed to verify the real-world effectiveness of this combination therapy in patients with\n                      <jats:italic>BRAF V600E<\/jats:italic>\n                      -positive PTC and ATC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively investigated adult patients with\n                      <jats:italic>BRAF V600E<\/jats:italic>\n                      -positive PTC and ATC who were treated with dabrafenib plus trametinib at a single university hospital in Japan.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between January 2024 and December 2024, 10 patients with PTC and 6 patients with ATC were identified, among whom 13 patients (81%) had been previously treated with lenvatinib. An objective response was observed in 5 patients with PTC (50%) and 4 patients with ATC (67%). The median progression-free survival and overall survival were not reached in patients with PTC, and were 2.7 months and 3.6 months, respectively, in patients with ATC. Partial regression of intracranial metastatic tumors was observed in 1 of the 2 patients with brain metastases at baseline. Rechallenge with another BRAF\/MEK inhibitor combination therapy, encorafenib plus binimetinib, was attempted in 2 patients with ATC and demonstrated clinically meaningful responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Dabrafenib plus trametinib combination therapy demonstrated clinical effectiveness in patients with\n                      <jats:italic>BRAF V600E<\/jats:italic>\n                      -positive thyroid cancer, with response rates comparable to those observed in clinical trials. However, tumor shrinkage did not appear to translate into improved survival in patients with ATC, highlighting the limitations of current targeted therapies in managing this aggressive subtype.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-025-02861-8","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T12:12:47Z","timestamp":1755864767000},"page":"2257-2265","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancer"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3009-0583","authenticated-orcid":false,"given":"Taiju","family":"Ando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Tomiie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Kuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatsuka","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"key":"2861_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2023.26348","volume":"331","author":"L Boucai","year":"2024","unstructured":"Boucai L, Zafereo M, Cabanillas ME (2024) Thyroid cancer: a review. JAMA 331:425\u2013435. https:\/\/doi.org\/10.1001\/jama.2023.26348","journal-title":"JAMA"},{"key":"2861_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1507\/endocrj.ej23-0342","volume":"71","author":"S Toda","year":"2024","unstructured":"Toda S, Iwasaki H, Okubo Y et al (2024) The frequency of mutations in advanced thyroid cancer in Japan: a single-center study. Endocr J 71:31\u201337. https:\/\/doi.org\/10.1507\/endocrj.ej23-0342","journal-title":"Endocr J"},{"key":"2861_CR3","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s12020-024-03738-y","volume":"85","author":"H Yamazaki","year":"2024","unstructured":"Yamazaki H, Kunisaki C, Sugimori M et al (2024) Genetic landscape of 482 thyroid carcinomas: analysis with the national datacenter for cancer genomic medicine in Japan. Endocrine 85:766\u2013776. https:\/\/doi.org\/10.1007\/s12020-024-03738-y","journal-title":"Endocrine"},{"key":"2861_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA et al (2023) Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med 29:1103\u20131112. https:\/\/doi.org\/10.1038\/s41591-023-02321-8","journal-title":"Nat Med"},{"issue":"4","key":"2861_CR5","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1089\/thy.2023.0547","volume":"34","author":"M Tahara","year":"2024","unstructured":"Tahara M, Kiyota N, Imai H et al (2024) A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan. Thyroid 34(4):467\u2013476. https:\/\/doi.org\/10.1089\/thy.2023.0547","journal-title":"Thyroid"},{"key":"2861_CR6","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/thy.2022.0115","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"Busaidy NL, Konda B, Wei L et al (2022) Dabrafenib versus dabrafenib + trametinib in braf-mutated radioactive iodine Refractory differentiated thyroid cancer: results of a randomized, phase 2. Open-Label Multicenter Trial Thyroid 32:1184\u20131192. https:\/\/doi.org\/10.1089\/thy.2022.0115","journal-title":"Open-Label Multicenter Trial Thyroid"},{"key":"2861_CR7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.4143\/crt.2023.1278","volume":"56","author":"Y Jeon","year":"2024","unstructured":"Jeon Y, Park S, Lee SH et al (2024) Combination of dabrafenib and trametinib in patients with metastatic BRAFV600E-mutated thyroid cancer. Cancer Res Treat 56:1270\u20131276. https:\/\/doi.org\/10.4143\/crt.2023.1278","journal-title":"Cancer Res Treat"},{"key":"2861_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/thy.2017.0285","volume":"28","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Dadu R, Ferrarotto R et al (2018) Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid 28:79\u201387. https:\/\/doi.org\/10.1089\/thy.2017.0285","journal-title":"Thyroid"},{"key":"2861_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1530\/eje-20-1482","volume":"184","author":"J Park","year":"2021","unstructured":"Park J, Jung HA, Shim JH et al (2021) Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience. Eur J Endocrinol 184:837\u2013845. https:\/\/doi.org\/10.1530\/eje-20-1482","journal-title":"Eur J Endocrinol"},{"key":"2861_CR10","first-page":"5342","volume":"12","author":"CF Chang","year":"2022","unstructured":"Chang CF, Yang MH, Lee JH et al (2022) The impact of BRAF targeting agents in advanced anaplastic thyroid cancer: a multi-institutional retrospective study in Taiwan. Am J Cancer Res 12:5342\u20135350","journal-title":"Am J Cancer Res"},{"key":"2861_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s12020-022-03295-2","volume":"80","author":"F Bueno","year":"2023","unstructured":"Bueno F, Smulever A, Califano I et al (2023) Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience. Endocrine 80:134\u2013141. https:\/\/doi.org\/10.1007\/s12020-022-03295-2","journal-title":"Endocrine"},{"key":"2861_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/ejendo\/lvac011","volume":"188","author":"TN da Silva","year":"2023","unstructured":"da Silva TN, Rodrigues R, Saramago A et al (2023) Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study. Eur J Endocrinol 188:31\u201338. https:\/\/doi.org\/10.1093\/ejendo\/lvac011","journal-title":"Eur J Endocrinol"},{"key":"2861_CR13","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/j.clon.2022.10.017","volume":"35","author":"C Lorimer","year":"2023","unstructured":"Lorimer C, Cheng L, Chandler R et al (2023) Dabrafenib and trametinib therapy for advanced anaplastic thyroid cancer\u2014real-world outcomes from UK centres. Clin Oncol (R Coll Radiol) 35:e60\u2013e66. https:\/\/doi.org\/10.1016\/j.clon.2022.10.017","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2861_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/cancers12020383","volume":"12","author":"L Fugazzola","year":"2020","unstructured":"Fugazzola L, Muzza M, Pogliaghi G et al (2020) Intratumoral genetic heterogeneity in papillary thyroid cancer: occurrence and clinical significance. Cancers (Basel) 12:383. https:\/\/doi.org\/10.3390\/cancers12020383","journal-title":"Cancers (Basel)"},{"key":"2861_CR15","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1002\/cncr.28187","volume":"119","author":"MR Haymart","year":"2013","unstructured":"Haymart MR, Banerjee M, Yin H et al (2013) Marginal treatment benefit in anaplastic thyroid cancer. Cancer 119:3133\u20133139. https:\/\/doi.org\/10.1002\/cncr.28187","journal-title":"Cancer"},{"key":"2861_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/eje-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG, Drilon A, Lin JJ et al (2022) Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 186:631\u2013643. https:\/\/doi.org\/10.1530\/eje-21-1259","journal-title":"Eur J Endocrinol"},{"key":"2861_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/s1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C et al (2017) Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18:863\u2013873. https:\/\/doi.org\/10.1016\/s1470-2045(17)30429-1","journal-title":"Lancet Oncol"},{"key":"2861_CR18","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/cancers15153754","volume":"15","author":"JN Priantti","year":"2023","unstructured":"Priantti JN, Vilbert M, Madeira T et al (2023) Efficacy and safety of rechallenge with BRAF\/MEK inhibitors in advanced melanoma patients: a systematic review and meta-analysis. Cancers (Basel) 15:3754. https:\/\/doi.org\/10.3390\/cancers15153754","journal-title":"Cancers (Basel)"},{"key":"2861_CR19","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA et al (2022) Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 33:406\u2013415. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014","journal-title":"Ann Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02861-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02861-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02861-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:13:13Z","timestamp":1761847993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02861-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2861"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02861-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6423355\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Ethics Committee (No. HM24-493).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained using an opt-out method approved by the institutional ethics committee. Information regarding the study was disclosed on the institution\u2019s website, and participants were given the opportunity to decline participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}